News | TCT | September 15, 2022

Valentin Fuster, M.D., Ph.D., Receives Prestigious Award from Cardiovascular Research Foundation

Dr. Valentin Fuster to be honored with the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Image courtesy of Mount Sinai Health System

Dr. Valentin Fuster to be honored with the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Image courtesy of Mount Sinai Health System 


September 15, 2022 — The Cardiovascular Research Foundation (CRF) will honor Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, with the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award

Dr. Fuster will receive this award September 17, at the 34th annual TCT scientific symposium, sponsored by CRF. The TCT Career Achievement award recognizes Dr. Fuster’s extraordinary contributions to the field of interventional cardiology and transformation of patient care through his career endeavors, research pursuits, and mentorship of others.
“I am grateful for this award and would like to recognize all the contributors who have inspired my work,” says Dr. Fuster.
Dr. Fuster's contributions to cardiovascular medicine and the prevention and treatment of heart disease globally are unparalleled. He has 35 worldwide honorary degrees and is the most highly cited Spanish research scientist of all time, according to Google Scholar. He is an author of more than 900 scientific articles in international medical journals and has published two leading books on clinical cardiology and research. Dr. Fuster has received three of the most important awards from the National Institutes of Health and is the only cardiologist to have received the highest awards for research from the four leading international cardiology organizations: the American College of Cardiology, American Heart Association (AHA), European Society of Cardiology, and Interamerican Society of Cardiology. He recently received Thailand’s Prince Mahidol Award in the field of Medicine, and this year, the AHA established the “Valentin Fuster Award for Innovation in Science” in his honor, naming him the first recipient. 

Dr. Fuster is Editor-in-Chief of the Journal of the American College of Cardiology (JACC), which ranks among the top cardiovascular journals in the world for its scientific impact. He is a past president of both the AHA and the World Heart Federation. He the General Director of the Spanish National Center for Cardiovascular Research (CNIC).  Dr. Fuster is a member of the National Academy of Medicine, where he served as chair of the Committee on Preventing the Global Epidemic of Cardiovascular Disease, and was a Council member of the National Heart, Lung, and Blood Institute. Dr. Fuster was also President of the Training Program of the American College of Cardiology. 

For more information: https://www.mountsinai.org 

Find more TCT22 coverage here  


Related Content

News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
Subscribe Now